You searched for myc - Page 2 of 10

Review of the new Zaret Cell paper on Myc & OSK in cellular reprogramming

November 29, 2012 / Professor Paul Knoepfler, Ph.D.

There’s a new paper out this week in Cell from the Zaret lab that is very exciting. In this manuscript, Facilitators and Impediments of the Pluripotency Reprogramming Factors’ Initial Engagement with the Genome, Zaret’s team explores how Myc and Oct4, Sox2, and Klf4 (OSK) behave at the genomic level during cellular reprogramming. What are the most […]

Review of the new Zaret Cell paper on Myc & OSK in cellular reprogramming Read More »

More on Myc: meet the “Miz’s” in our new paper

November 13, 2011 / Professor Paul Knoepfler, Ph.D. / 1 Comment

I recently did a post telling you about one of my favorite molecules, Myc, which is important not only in cancer but also in most, if not all stem cells including iPS cells. There’s a lot more to Myc and how it does it’s tricks in embryonic stem cells and iPS cells. It cannot do

More on Myc: meet the “Miz’s” in our new paper Read More »

Want to understand stem cells? Then you have to know Myc

November 6, 2011 / Professor Paul Knoepfler, Ph.D. / 1 Comment

What is Myc? Often when we dig a little into the science of stem cells, people get turned off by all the strange names of molecules and jargon. However, whether you are a scientist, patient, investor, reporter, etc. there are some aspects of stem cell science that are ‘musts’ to know about. For example, you

Want to understand stem cells? Then you have to know Myc Read More »

New iPS cell method: drop Myc or not yet?

June 8, 2011 / Professor Paul Knoepfler, Ph.D. / 4 Comments

human-IPS-cells-made-in-Knoeplfer-lab-stained-for-TRA-160

Yamanaka may have found a way to give exogenous Myc the boot from the iPS cell universe. It has always been a frustration in the iPS cell field that Myc, a proto-oncogene, is so important for reprogramming. Yes, you can make iPS cells (especially mouse) without Myc, but it can be orders of magnitude harder,

New iPS cell method: drop Myc or not yet? Read More »

Tumorigenicity and Pluripotency teased apart? Not yet for Myc

August 2, 2010 / Professor Paul Knoepfler, Ph.D.

Fig.-5-Nakagawa-et-al.-Myc-in-cancer-and-IPScs

A paper just came out in PNAS entitled “Promotion of direct reprogramming by transformation-deficient Myc“. The main thrust of this paper is that the tumorigenic and pluripotency-related functions of Myc could be separated. It focused primarily on the lesser studied LMyc. The topic of the intertwined good (pluripotency) and bad (tumorigenicity) functions of Myc, addressed

Tumorigenicity and Pluripotency teased apart? Not yet for Myc Read More »

A close look at in vitro gametogenesis or IVG: making sperm & eggs from stem cells to have kids

February 26, 2025 / Professor Paul Knoepfler, Ph.D. / 3 Comments

There is growing interest in a possible new reproductive method based on something called in vitro gametogenesis or IVG. Today’s post explains IVG including its potential pros and cons. I also discuss why its possible combination with gene editing is so potentially fraught, which is a big potential con. Let’s start with an explanation of this

A close look at in vitro gametogenesis or IVG: making sperm & eggs from stem cells to have kids Read More »

Weekly reads: Altos Labs aging supplements pub, destructive NIH cuts, FDA warning, HSCs

February 9, 2025 / Professor Paul Knoepfler, Ph.D. / 3 Comments

When I think of so-called aging supplements, visions of snake oil dance in my head. Possible benefits of supplements more generally have mostly not held up to long-term research. Supplements have risks too and so do purported longevity supplements. These pills claiming to fight aging are more in the realm of stem cell supplements that

Weekly reads: Altos Labs aging supplements pub, destructive NIH cuts, FDA warning, HSCs Read More »

Weekly reads: FDA modernization, TFs on the brain, mortality timer, pluripotent trials

January 19, 2025 / Professor Paul Knoepfler, Ph.D. / 1 Comment

How will things change at the FDA under the second Trump Administration? It’s a key question for our field but not easy to answer. Most likely there will be more instability at the agency. Some leaders, like of CDER, have already left. in my overall regenerative medicine predictions for 2025, I’ve included more predictions about

Weekly reads: FDA modernization, TFs on the brain, mortality timer, pluripotent trials Read More »

25 stem cell & regenerative medicine predictions for 2025

December 17, 2024 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

regenerative medicine, stem cell predictions

Toward the end of each year I make predictions for the stem cell and regenerative medicine field for the coming year. I’ve been doing this for more than a dozen years in various forms. In this post I’m looking at the (gene-edited, stemness enriched) tea leaves for 2025 for the regenerative arena. These predictions include

25 stem cell & regenerative medicine predictions for 2025 Read More »

Search Results for: myc